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Summary 
The N-terminus portion of the POMC leader 
sequence (signal peptide) was synthesized, and 
an antiserum was raised against it. A radio- 
immunoassay was developed which is effective at 
a dilution of 1:500,000, and sensitive at less 
than 1 fmole/tube. Since leader sequences often 
exhibit structural homologies, and since 
synthetic peptides are not readily available, we 
resorted to an unusual procedure to establish 
specificity. This involved extraction of 
pituitary RNA, cell-free translation to produce 
the pre-prohormones, and purification by B-END 
and signal antibody affinity columns. The 
eluates were then tested by SDS gel electrophor- 
esis and by multiple immunoprecipitations. All 
results showed that the signal antibody captured 
a single molecular species, approximately 30,000 
in MW, which was also captured by the B-END 
column, and was immunoprecipitable by B-END and 
ACTH antisera. It therefore appears that this 
antibody selectively measures the POMC leader 
sequence and should be valuable in measuring the 
newly synthesized pre-prohormone. 
Most measures of B-END in brain and pituitary have been 
confined to assessing total levels. The other approach, useful 
in pituitary, is the pulse chase experiment, which is powerful 
but rather cumbersome. Since the B-END-ACTH precursor, 
pro-opiomelancortin (POMC) has been shown to have a leader 
sequence or signal peptide (l), and since this peptide is only 
thought to be intact while the precursor is on the ribosome (2), 
we set out to establish an assay for that region. The rationale 
is that an assay which measures either free POMC signal or the 
full pre-prohormone (POMC + signal), would measure newly 
synthesized material. Work in other systems (3) suggests that 
the half life of the pre-prohormone is very short, on the order 
of a few minutes. Thus a POMC-signal assay, when coupled with a 
total PCMC and/or B-END assay, can yield an estimate of current 
synthesis versus total content. As such, it may provide us with 
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a dynamic measure of the activity in a POMC system, with the 
simple device of two radioimmunoassays. It would also allow us 
to study the kinetics of transformation from POMC pre-prohormone 
to prohormone in pulse chase experiments. 
The main difficulties arising are: 1) the synthesis and 
handling of the leader sequence, since it contains many leucines 
and isoleucines, and tends to be highly hydrophobic. 2) the 
validation of this assay, since many leader sequences posess 
structural homologies, which render cross reactivity quite 
likely. Yet, other leader structures are not readily available 
for such tests. Ye therefore had to resort to an unusual 
approach to validate our system and show its usefulness. This 
report describes this validation process. 
Methods 
The N-terminus of the POMC leader sequence, and the 
N-tyrosine version of it (for iodination) were synthesized by 
solid phase techniques. The peptide was coupled with 
gluteraldehyde to thyroglobulin, and the antiserum raised in 
rabbit. The various bleeds ranged in tit755 from 1:40,000 to 
1:500,000 under RIA conditions using the I-signal peptide as 
a tracer, with sensitivity of 0.5 fmoles and IC of about 10 
fmolesjtube. In order to validate the assay, 5gh e antibody was 
affinity purified by passing it through a signal peptide 
affinity column. Then the purified IGg was itself coupled to 
sepharose 4B to form the signal antibody column under study. A 
similar B-END antibody column was also built and had been 
previously shown (in pulse chase and other experiments) to 
capture only POMC, B-LPH and B-END. 
In order to obtain POMC with the leader sequence attached, 
we used pituitary cell free translations, since no signal 
peptidase activity is present in these systems. Total pituitary 
RNA was extracted with phenol/CHC13/isoamyl alcohol, using the 
method of Ross (4). The total RNA was translated using a rabbit 
Sgticulocyte lysate system (NEN) in the presence of 
S-methionine. The translation products were then partially 
purified on Sep Pak to separate protein from free radioactive 
methione. 
At that point we had a mixture of proteins translated from 
pituitary RN'A and presumably containing a number of 
pre-prohormones with their leader sequences. The translation 
product was then split in half with one portion applied to the 
B-END antibody affinity column and the other to the signal 
antibody affinity colunn. After extensive washing in NaPB, the 
material was eluted off both columns with 2N acetic acid. A 
portion of each eluate (40%) was re-applied to the original 
column while another portion (40%) was "crossed" i.e., applied 
to the column it had not been on. Eluates from this second set 
of runs were tested on disc gel SDS electrophoresis to determine 
the number of molecular species captured, and their molecular 
weights. 
Finally, a portion of the eluates of the second runs were 
pooled and used for immunoprecipitation studies. In these, 
antisera against the signal region, the B-END region and the 
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ACTH17-24 
region of POMC were added with or without the 
appropriate blocking peptide. After double antibody 
precipitation, the immunoreactive materials were also tested 
with SDS disc gel electrophoresis. 
Results 
Gels from the eluates of both the B-END antibody column and 
the signal antibody showed a single 30,000 MW peak (expected 
weight of unglycoylated POMC with leader attached). Further- 
more, the material captured by the B-END antibody was also 
captured by the signal antibody and vice versa (recovery in both 
cases over 95%). This was evidenced by results of the second 
set of column tests, whereby "crossed" and "uncrossed" materials 
all showed the same 30,000 MW peak. Finally, the material 
passed through both columns was immunoprecipitable by B-END 
leader and RCTH antisera, and these were only blocked by the 
proper peptide. 
These results all show that: 1) The signal antibody column 
captured a single 3OK molecular species out of a mixture of 
pituitary pre-prohomones, 2) this same molecular species was 
also captured by the B-END antiserum (and not by a control anti 
BSA column), and was im?munoprecipitable by B-END and ACTH 
antisera, strongly suggesting that the material is indeed POMC. 
Conclusions 
The harvesting of an anti-signal peptide antiserum and the 
use of this approach for validation of assay specificity allows 
us to measure the signal portion of POMC. Early chromatographic 
studies using the RIA thus validated shows that the material 
being assayed is primarily the pre-prohormone (MW:30K) and not 
the free signal peptide. POMC signal immunoreactivity is 
differentially distributed in tissue, being highest in pituitary 
and not detectable in striatum. The levels in general are less 
than 1% of total POMC levels. This assay should be valuable in 
studying the dynamics of POMC synthesis. 
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